GlaxoSmithKline plc (GSK)
| Market Cap | 99.40B |
| Revenue (ttm) | 44.42B |
| Net Income (ttm) | 7.20B |
| Shares Out | 2.52B |
| EPS (ttm) | 2.86 |
| PE Ratio | 13.81 |
| Forward PE | 14.95 |
| Dividend | $2.13 |
| Dividend Yield | 5.38% |
| Trading Day | July 23 |
| Last Price | $39.51 |
| Previous Close | $39.23 |
| Change ($) | 0.28 |
| Change (%) | 0.71% |
| Day's Open | 39.50 |
| Day's Range | 39.38 - 39.60 |
| Day's Volume | 2,129,197 |
| 52-Week Range | 31.83 - 41.44 |
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NASDAQ: GSK), which started a 35,000-patient Phase 3 trial in ...
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral hypoxia-inducible factor prolyl hydroxyl...
GlaxoSmithKline plc (NYSE: GSK) is planning to sell more than one-third of its 92-acre R&D site in Stevenage, the U.K. The Company is looking to sell 33 acres of the site and unlock up to £400 million ...
Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising 400 million pounds ($552.76 million) through the sale of some l...
The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare.
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccin...
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.
It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.
One of these companies is making big waves.
GlaxoSmithKline plc (NYSE: GSK) said its board sees Chief Executive Emma Walmsley as the right person to lead its pharmaceutical business after the upcoming split with its consumer-health unit. The boar...
Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Se...
Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranuli...
An activist investor seems to be pushing for one.
GSK on Friday backed Chief Executive Emma Walmsley to continue leading the pharmaceuticals group after it spins off its consumer healthcare arm, responding to activist investor Elliott's proposals for t...
Activist Fund Elliott Management Wants GlaxoSmithKline Board Shakeup For 'Years Of Under Management'
Elliott Management has finally made its intentions around GlaxoSmithKline plc (NYSE: GSK) known and calls for changes to rescue GSK from what it called "years of under-management." In an open letter to ...
The three stocks listed below could be of interest to growth-oriented investors, as they represent equities in businesses whose price-earnings ratios are below 20 while their trailing 12-month earnings ...
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
The shares of GlaxoSmithKline plc (NYSE:GSK) are up 0.4% at $39.96 this morning, following news that Elliott Management has urged the British pharmaceutical company to name a new set of board directors ...
Activist fund Elliott, which has taken a "significant" stake in pharmaceuticals group GSK, has written to the British company's board setting out five main recommendations to improve the company's perfo...
The sample size was small, but the results were impressive.
Activist investor Elliott urged GlaxoSmithKline to consider the sale of its consumer healthcare business, which is being listed next year and said it saw scope to drive up the value of the group.
Reposition your portfolio for dividend yields, says Ariel's Bhansali
Rupal Bhansali, Ariel International Fund & Ariel Global Fund portfolio manager, discusses her approach to investing right now as well as her top picks for the second half of the year.
WARREN, N.J., June 29, 2021 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – Get ready for a red hot American summer!
While sustainable initiatives sound like a strategy for non-profit organizations, shifting demographics bode well for ESG stocks. The post The 7 Best ESG Stocks to Buy for the Biggest (Socially Responsi...
Goldman Sachs and Citi are working with GlaxoSmithKline on new listing for a spinoff of its consumer unit, Bloomberg writes. The companies will also help with Glaxo's defense against the possibility of ...
GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management, Bloomberg News r...
On Wednesday, British multinational pharmaceutical giant GlaxoSmithKline PLC ( GSK , Financial) revealed a sweeping strategic transformation plan aimed towards growing the company's profits and performa...
This low interest-rate environment hasn't dragged all dividend yields sharply lower as a result.
The shares of London-based GlaxoSmithKline PLC (NYSE:GSK) are up 3.5% to trade at $40.45 at last check, after the global healthcare company announced plans to spin off its consumer health business.
Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV
GlaxoSmithKline plc (LON: GSK) said on Wednesday its consumer healthcare business will be spun off into a separately listed company. The demerger that was originally announced in December 2018 will even...
Britain's GSK set out detailed plans on Wednesday to turn its consumer healthcare arm into a separately listed company, in a move that will bolster the finances of the remaining business to help fund dr...
British pharmaceutical giant GlaxoSmithKline faces a crunch meeting with investors after announcing a new strategy for the next decade.
GlaxoSmithKline CEO on spinoff of consumer health-care business
GlaxoSmithKline's stock rose 3.5% in the premarket Wednesday after it detailed plans to spin out its consumer health-care business into a separate company. Glaxo will eventually receive an $11 billion p...
GSK set out plans on Wednesday to turn its consumer healthcare business into a separately listed company, aiming to strengthen drug development at its pharmaceuticals business with an 8 billion pound ($...
Britain's GSK on Wednesday unveiled a detailed plan to spin off its consumer healthcare venture with Pfizer into a separate company by the middle of next year, as the pharmaceutical giant sharpens its f...
Jim Cramer: What to watch for at GlaxoSmithKline investor day
"Either Emma Walmsley tells a great story tomorrow and gives people more reason to own it, or she tells a suboptimal story and Elliott Management pushes for new leadership," the "Mad Money" host said.
Investors should be prepared for the stock to get slammed if GlaxoSmithKline moves to cut its dividend, the "Mad Money" host said.
Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make b...
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's Enhanze dr...
LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholder...
GlaxoSmithKline PLC ( GSK , Financial) investors are likely to find out this Wednesday just how much support Elliott Management can muster for the dramatic changes the activist investor is proposing for...
GlaxoSmithKline Plc's (NYSE: GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical change at the company, the Financial Times reported cit...
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mi...
GlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day on Wednesday, as analysts call on the British drugmaker to boost drug d...
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression ...
23andMe CEO on Trading Debut, GSK Deal, Branson SPAC
Jun.17 -- 23andMe Inc. CEO Anne Wojcicki discusses the DNA-testing company's NASDAQ trading debut, a collaboration on drug development with GlaxoSmithKline Plc, and the choice to go public through a mer...
About GSK
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, ... [Read more...]
| Industry Drug Manufacturers-General | Founded 1715 |
| CEO Emma Walmsley | Employees 94,066 |
| Stock Exchange NYSE | Ticker Symbol GSK |
Financial Performance
In 2020, GSK's revenue was 34.10 billion, an increase of 1.02% compared to the previous year's 33.75 billion. Earnings were 5.75 billion, an increase of 23.77%.
Analyst Forecasts
According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 49.17, which is an increase of 24.45% from the latest price.